Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Cardiology
•
Interventional Cardiology
What is your preferred duration of aggrastat therapy, and does it differ if patient presented with NSTEMI versus STEMI?
Related Questions
What has been your approach to percutaneous intervention for calcified nodules and threshold for intervention?
For SVG graft stenting, do you consider routinely embolic protection devices (EPD), and do you factor lesion location (prox vs distal) for decision making?
Do you recommend routine use of protamine for hemostasis at the end of a transfemoral TAVI?
Would you recommend normal saline for pre- and post-LHC hydration in patients with CKD stage III to IV with reduced LV systolic function, and if so, what is a reasonable amount of volume?
How would you approach the timing of hemodialysis for an ESKD patient with no urgent indications who has NSTEMI with a troponin level of 10 ng/dl, has not had dialysis in 2 days, and is planned for left heart catheterization the next day?
Do you avoid high-potency P2Y12 inhibitors in favor of clopidogrel in patients with atrial fibrillation on a DOAC who undergo PCI?
Would you consider an inpatient Mitraclip for patients with severe MR and severely reduced LVEF who have been turned down/high risk for surgery if there were ongoing challenges with afterload reduction and transitioning to intermittent dialysis due to recurrent flash pulmonary edema?
How do you decide between opting for semi-elective outpatient versus inpatient TAVR for patients with severe critical AS?
What is/are your preferred technique(s) for obtaining LV-Ao pressure gradients in the cath lab?
How do you approach the decision of when to perform left heart catheterization in a patient with an NSTEMI who recently had an acute ischemic stroke?
